Canaccord Genuity Upgrades Aerie Pharmaceuticals To Buy

by Monica Gerson, Benzinga Staff Writer
June 19, 2015 10:08 AM | 16 seconds read |
Canaccord Genuity upgraded Aerie Pharmaceuticals Inc AERI from Hold to Buy. Aerie Pharmaceuticals shares have gained 1.57 percent over the past 52 weeks, while the S&P 500 index has surged 8.07 percent in the same period. Aerie Pharmaceuticals' shares rose 10.73 percent to $22.18 in pre-market trading.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesAnalyst RatingsCanaccord Genuity
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!